A federal advisory committee supports booster shots of all three COVID-19 vaccines being used in the US for Americans who need them.
So far, only the Food and Drug Administration has Authorized Booster Dose of Pfizer-BioNtech Vaccine for certain people who may be at high risk for COVID-19 infection or serious illness.
But the other two vaccines are working their way through the regulatory process and booster shots are likely to be available to some people soon.
On Thursday, the FDA’s advisory panel — called the Vaccines and Related Biological Products Advisory Committee — voted unanimously. Moderna Vaccines Booster Support for a limited population. The same committee voted unanimously Support second dose of Johnson & Johnson vaccine on Friday.
The FDA’s acting commissioner is likely to sign off on the committee’s decision in the next few days. On October 20 and 21, a separate independent committee of experts will review the same data and make a recommendation to the head of the Centers for Disease Control and Prevention. Only if she decides to support the boosters will they be available to the public.
About 15 million adults in the US have been fully vaccinated with the one-dose J&J vaccine, compared to 103 million who received Pfizer and 69 million who received Moderna, both on a two-dose regimen. So far, 8.8 million Americans have received a booster dose of the Pfizer vaccine.
The Biden administration said it has already purchased enough doses of the COVID-19 vaccine to make it available to Americans at no cost.
Here’s who is and is expected to be eligible for a booster dose of all three vaccines.
FDA authorizes booster dose of Pfizer-BioNTech vaccine for people 65 and olderwhose jobs put them at higher risk of exposure to COVID-19.
Individuals 18 years of age and older who are at high risk for severe COVID-19 were also included in the authorization, which only covers those who are at least six months out of their second dose of the vaccine. Huh.
High-risk jobs include “health care workers, teachers and day care staff, grocery workers and homeless in shelters or prisons,” said FDA Executive Commissioner Dr. Janet Woodcock said.
More than 20 million Americans are eligible for Pfizer booster shots, and more than 40 million people will have access six months after their second shot.
CVS and Walgreens announced shortly after authorization that they were offering a booster dose of the Pfizer vaccine to eligible people. However, the pharmacy chain said they were not taking additional steps to police qualifications to “remove barriers and improve access to potentially life-saving vaccines”, leaving room for dishonesty.
The VRBPAC voted Thursday to support booster shots of the Moderna COVID-19 vaccine for the same group who received the Pfizer vaccine: people 65 years of age and older, and young adults with certain medical problems or jobs who putting them at risk of infection.
Committee members said these jobs could include health care workers, grocery store clerks and others potentially exposed to COVID-19 doing their jobs.
The booster shot will be half the dose of the same vaccine that has already been given. The company’s data suggested that the lower dosage was just as effective but potentially had fewer side effects.
People who are immunized because of an organ transplant, cancer treatment, medication, or a similar condition may have already received a full third dose of Moderna vaccine.
johnson & johnson booster
The federal advisory panel said the J&J vaccine should be considered a two-dose vaccine, rather than a single-dose vaccine, which received initial authorization.
VRBPAC realized that 15 million Americans who had received one dose of the “gone more” J&J vaccine would be much better protected with the other. The committee voted unanimously to support the “booster” of the J&J shot, at least two months after the initial dose was given.
Adding a second dose two to six months after the J&J shot will provide a similar efficacy to mRNA vaccines without their fading protection, Dr. Penny Heaton, head of vaccines global therapeutics at Jenson Pharmaceuticals, Johnson & Johnson. Vaccine development company.
Like Moderna, the committee’s decision on J&J’s second dose will need to be verified by a separate advisory panel as well as by top federal officials before it becomes available to the public.
The CDC said a single dose of the J&K vaccine would still be considered a complete vaccine.
Can you mix and match vaccines?
As of Friday, the CDC continues to recommend that people receive additional doses of the same vaccine they received the first time. FDA committee discussed on Friday National Institutes of Health study on mixing and matching vaccine boosters, but said more data was needed before it could be suggested that people be allowed to receive a booster shot separately from their original vaccine.